Catalyst

Slingshot members are tracking this event:

OncoSec's (ONCS) ImmunoPulse Il-12 Granted Fast Track Status by FDA for Metastatic Melanoma Following Progression on Merck's (MRK) KEYTRUDA or Bristol-Myers Squibb's (BMY) Opdivo

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
BMY

100%
MRK

100%
ONCS

100%
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 27, 2017
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Immunopulse Il-12, Fast Track Status, Metastatic Melanoma, Keytruda, Opdivo